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Nonsteroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed for orthopaedic 
FRQGLWLRQVWKHUHIRUHWKLVVWXG\DLPHGWRH[SORUHRUWKRSDHGLFSK\VLFLDQV¶SHUFHSWLRQVRIWKHLU
role in NSAID-risk communication, their attitudes towards the necessity of informing patients 
about adverse drug reactions (ADR), and factors associated with these. Attitudes were assessed 
using 17 statements and total scores classed as poor, moderate and good attitude. Self-
administered questionnaires were mailed to all 206 orthopaedic physicians working at hospitals 
in Northeastern Thailand and 66 were returned (32.04%). The responses showed that 75% of 
physicians claimed to communicate NSAID ADR information, more frequently about 
gastrointestinal (GI) complications, than about renal and cardiovascular (CVS) complications. 
ADR management (36%) and monitoring (30%) were not frequently communicated. The time 
spent with patients was associated with provision of ADR and monitoring advice. Renal 
function was the risk factor of greatest concern for prescribing any NSAID, followed by history 
of GI complications, and allergy for non-selective NSAIDs, and history of CVS diseases and 
age for selective COX-2 NSAIDs. Most physicians (41) had moderate attitude towards 
providing information and 24 good attitude. Fewer physicians working in tertiary hospitals than 
general and community hospital physicians considered that time limitations prevented 
counseling and that patient information leaflets offered easily accessible information. 
Additionally, more physicians who did not inform patients about ADRs agreed that ADR 
communication can lead to anxiety and discontinuing treatment. The study indicates that, 
although orthopaedic physicians had positive attitudes towards providing ADR information to 
patients, improvement is needed in communicating NSAID risk information.  






Communication of potential risks related to treatment is necessary to make patients be aware 
of concurrent benefits and risks of treatment in shared decision making about their treatment.
Thus achieving treatment goals and improving treatment safety may be ensured.1,2,3 Moreover, 
effective treatment risk information delivery also depends on the method of risk information, 
as this may have an impact on patients' understanding and decision-making.4 In practice, there 
are several aspects to be considered by healthcare professionals when communicating risks of 
WUHDWPHQW WKDW LV SDWLHQWV¶ OLWHUDF\ SDWLHQWV¶ DJH VRFLDO PHGLD/internet access and literacy, 
SKDUPDFHXWLFDOFRPSDQ\UROHDQGLQIOXHQFHSDWLHQWV¶H[SHFWDWLRQVEHOLHIVDQGFRQFHUQVDV
well as healthcare professionals' practice and behavior, all of which might affect the quality of 
risk information transferred to patients.1,5 A study found that the quality of consultation could 
LPSDFWRQERWKSDWLHQWV¶TXDOLW\RIOLIHDQGVDWLVIDFWLRQ6 while a qualitative study suggested 
that time-limited counseling, physicians' attitudes and communication skills were a potential 
barrier in providing treatment risk information and ensuring shared decision making with 
patients.7 
Several studies have shown that patients need to understand the possible risks including 
side effects of drugs, and that this information should be more freely shared with patients.8-11 
While majority of patients believe that healthcare professionals are highly-trusted sources of 
information and decisional support,12 some health professionals have concerns about the 
potential negative effects of providing treatment risk information on patients' adherence to the 
treatment, hence they may avoid providing full information.8 Previous studies showed that 
receiving good information from healthcare professionals13,14 and adequate patient±physician 
communication had a positive LPSDFW RQ SDWLHQWV¶ awareness about drug risks15 as well as 
health outcomes.16 Nevertheless, studies also confirm that the risks of treatment are not 
discussed routinely with all patients.17,18 
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Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used to manage pain 
and inflammation in clinical practice. Both their therapeutic and adverse effects are dependent 
on their ability to inhibit cyclooxygenase (COX) enzymesThe risk of developing adverse 
effects from NSAIDs depends on patient age, underlying diseases, and concomitant drug use. 
Healthcare professionals therefore should be more aware of these factors2022 Despite their 
common use a previous survey in the United States found NSAID users had poor awareness of 
NSAID risks, as well as their own risk factors 3DWLHQWV¶SHUFHSWLRQVRI16$,'ULVNVZHUH
relatively low and they often lacked knowledge about the common adverse effects.24 A recent 
study in Thailand found the majority of hospital pharmacists claimed they provided NSAIDs-
related adverse drug reaction (ADR) to patients, but rarely monitored parameters for potential 
ADRs and less frequent managed potential ADRs.25 Only about 40% of Thai patients taking 
NSAIDs said that they had received any side effect information, while less than 20% had 
received information about monitoring and management of these.26 As a prescribers, physicians 
are one of key healthcare professionals who play an important role in providing medication 
risk information. Based on risk information of NSAIDs, orthopaedic physicians also have a 
great potential for prescribing and providing safety information to patients directly. 
1HYHUWKHOHVVWKHUHDUHOLPLWHGVWXGLHVWKDWIRFXVHGRQ7KDLSK\VLFLDQV¶DZDUHQHVVRIWKHLUUROH
in informing medication risks. 
This study aimed to survey hospital ortKRSDHGLFSK\VLFLDQVµVSUDFWLFHV LQ LQIRUPLQJ
patients about NSAIDs adverse effect profiles, and to determine their awareness of the 
prescribed NSAIDs adverse effect profiles. Additionally, we surveyed the physicians' attitudes 
towards providing adverse drug reaction (ADR) information to patients and factors associated 
with them. 
2. METHODOLOGY 
2.1 Study design and setting 
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A cross-sectional study was conducted over a period of July to October 2012. The developed 
questionnaire was mailed to collect data from Thai orthopaedic physicians, who were presently 
working at hospitals in the North-eastern region. 
2.2 Participants 
Our participants were orthopaedic physicians who were working at hospitals in Northeastern 
Thailand, the largest region with the greatest rural population density. In 2012, a total of 206 
orthopaedic physicians were listed in the database obtained from The Royal College of 
Orthopaedic Surgeons of Thailand (From: http://www.rcost.or.th). Due to the limited number 
of physicians, we included all orthopaedic physicians in this survey. 
2.3 Questionnaire development 
A questionnaire was chosen for data collection. The four main parts of the questionnaire were 
specifically developed for this target population and covered: demographic data, roles in 
providing safety information for prescription NSAIDs, awareness of patient factors increasing 
NSAID risks, attitudes towards the importance of communication about ADRs to patients. If 
physicians responded that they provided ADR information from NSAIDs DQGUHDOL]HGSDWLHQWV¶
risk factors for ADRs from NSAIDs, details of ADRs and the risk factors concerned were 
collected using multiple response questions, with an additional information section in each 
question. A 5-point Likert scale was used to measure physicians' attitudes, which had a scale 
of 5 (strongly agree) to 1 (strongly disagree). The attitude section was composed of 17 
statements that focused on three aspects, i.e. need for providing ADR information to patients 
(statement no. 1-8), providing patient information leaflets (statement no. 9-14), and the roles 
of pharmaceutical companies in preparing patient information leaflets (PILs) (statements no. 
15-17). Content validity of the questionnaire was assessed by three experts (one orthopaedic 
physician and two pharmacists), the Index of consistency (IOC) was 0.92. Subsequently, the 
questionnaire was pilot tested with twenty physicians before data collection. Because of limited 
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number of orthopaedic physicians, physicians working in different departments were invited 
for pilot study, but these data were not included in the main results. After pilot testing, changes 
were made to reduce the length of questionnaire and increase the ease of use of some questions. 
2.4 Data collection 
The developed questionnaires with covering letter and return envelope were distributed by mail 
to 206 orthopaedic physicians. After sending the questionnaire at 3 weeks, reminder postcards 
were sent to non-responders. Data were collected between July and October 2012. 
2.5 Data analysis 
The completed questionnaires were recorded and analyzed by using IBM SPSS for Windows 
(version 19.0). The score for negative attitude statements were transformed by reverse scoring. 
The range of total attitudinal scores was 17 to 85, which was divided equally into three parts 
being classified as poor (17±40), moderate (41±63) and good attitudes (64±85). Respondent 
demographics, informing patients of ADRs, awareness of patients' risk factors in prescribing 
NSAIDs, and attitudes were reported as frequencies. The univariate analysis was conducted 
comparing all demographic data with ADR informing, attitude towards providing ADR 
information. Then, logistic regression was used to determine factors associated with ADRs 
LQIRUPLQJDQGOHYHORIWKHSK\VLFLDQV¶DWWLWXGH 
2.6 Ethics 
The research project was approved by the Khon Kaen University Ethics Committee for Human 
research, protocol number HE551130. 
3. RESULTS 
3.1 Response rate 
Of the 206 orthopaedic physicians contacted, 66 completed and returned the questionnaire 
(response rate 32.04%); 51 questionnaires were returned in first response, and another 15 
questionnaires after the reminder. Respondent demographics are summarized in Table 1. 
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(Insert Table 1 here) 
The majority of orthopaedic physicians were male (N=61, 92.4%). The mean age of 
respondents was 38.94±9.46 years (range 24 to 66 years) and 31.8% (N=21) were orthopaedic 
instructors. The mean work experience was 9.42±8.09 years (range 8 months to 30 years). Half 
of all respondents (N=38, 55.58%) were working in tertiary hospital, 25.76% (N=17) in general 
hospital and 16.67% (N=11) in community hospital. Moreover, there was a statistically 
significant difference between physicians working in different hospitals in term of work 
position, number of patients seen per day, and the amount of time spent with patients. 
3.2 3K\VLFLDQV¶FRPPXQLFDWLRQDERXW16$,'V 
When prescribing NSAIDs, 75% of all respondents (N=48) reported they informed patients 
about ADR information concerning NSAIDs. However, less than half claimed to provide 
information on ADR management (N=24, 37.5%) and monitoring (N=19, 29.7%) to patients. 
For details of ADR information, gastrointestinal risks were those mostly identified as being 
communicated, such as dyspepsia (N=61, 95.3%), gastrointestinal ulcer (N=54, 84.4%), and 
gastrointestinal bleeding (N=40, 62.5%).These were followed by renal impairment (N=36, 
56.3%), while cardiovascular effects were rarely identified, except high blood pressure (N=10, 
15.6%) 
A multivariate analysis, illustrated in Table 2, found a statistically significant difference 
in provision of ADR information. Physicians who spent more than 50% of all working hours 
in contact with patients were less likely to provide the patients with ADR information (ORadj 
0.249, 95%CI 0.074-0.837). Moreover, physicians who spend more than 5 minutes for 
diagnosis and advising patients were significantly less likely to inform patients about ADR 
monitoring (ORadj 0.297, 95%CI 0.091-0.968), while physicians who had direct contact 
withpatients more than 50% of all their working hours were more likely to inform about ADR 
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monitoring (ORadj 3.363, 95%CI 1.033-10.947). However, no significant difference was found 
in informing about ADR management for all related factors. 
(Insert Table 2 here) 
3.3 Awareness of patient risk factors to NSAID ADR before prescribing 
The physicians reported that diclofenac (60.0%) and ibuprofen (26.7%) were commonly 
prescribed for patients. In practice, dyspepsia (N=56, 82.6%), high blood pressure (N=44, 
72.1%), and renal impairment (N=36, 57.1%) were identified as common adverse effects 
relating to gastrointestinal, cardiovascular, and renal system, respectively. 
(Insert Table 3 here) 
The risks of concern when prescribing NSAIDs to patients were divided into non-
selective NSAIDs and selective COX-2 NSAIDs. The top five patient risk factors of which the 
physicians were mostly aware were presented in Table 3. History of renal impairment (N=65, 
98.5%), GI ulcer-bleeding (N=63, 95.5%), and allergy to NSAIDs (N=56, 84.8%) were the 
patient factors that majority of physicians took precaution before prescribing non-selective 
NSAIDs. For selective COX-2 NSAIDs, history of renal impairment (N=57, 86.4%) was 
identified by more than 80% of all physicians. Approximately 70% (N=47), and 68% (N=45) 
were concerned about history of cardiovascular disease and patient age, respectively. In 
addition, less than half of all physicians identified concomitant drugs, such as aspirin, 
anticoagulants, antihypertensive drug, corticosteroids, as a risk factor for ADRs from NSAIDs. 
3.4 3K\VLFLDQV¶DWWLWXGHWRZDUds providing ADR information to patients 
There were 65 orthopaedic physicians who answered the attitude part of the questionnaire. 
More than half of all these physicians had a moderate attitude towards the importance of 
providing about ADR information to patients (N=41, 63.1%), none of them had a poor attitude, 
and no statistically significant difference was found in level of attitude between physicians 
working in different hospitals. The average score of attitude was 61.15±5.30 
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From Table 4, total mean sFRUHVRISK\VLFLDQV¶DWWLWXGHZHUHQRWVWDWLVWLFDOO\VLJQLILFDQW
different in all type of hospitals, and providing/not providing ADR information. However, there 
were significant differences (P<0.05) in two statements in type of hospitals, and providing/not 
providing ADR. Most physicians who working in general and community hospitals agreed that 
ADR communication can be time-consuming (N=26, 96.3%, compared to 73.7% in tertiary 
hospitals) and patient information leaflets may be easily accessed for ADR information by 
patients (N=26, 96.3%, compared to 71.1% in tertiary hospitals). Additionally, a high 
proportion of physicians who claimed not to provide ADR information to patients agreed that 
ADR communication can cause anxiety (N=11, 68.8% in non-ADR advice group, compared to 
34.0% in ADR advice group) and lead to discontinuing treatment in patients (N=10, 62.5% in 
non-ADR advice group VS 23.4% in ADR advice group). 
(Insert Table 4 here) 
4. DISCUSSION 
When prescribing NSAIDs, the results of our study demonstrated that a history of renal 
impairment was the first concern for both non-selective NSAIDs (98.5%) and selective COX-
2 NSAIDs (86.4%). History of gastrointestinal ulcer/bleeding and NSAID allergy were the 
second and third concern for nonselective NSAIDs, while history of cardiovascular disease and 
patient age were the second and third for selective COX-2 NSAIDs. Long-term use of NSAIDs 
was agreed as a concern in prescribing non-selective NSAIDs (79%) and COX-2 NSAIDs 
(59%) of physicians, while concomitant use of drugs which have the potential to interact with 
NSAIDs (such as anticoagulants, corticosteroids, some groups of antihypertensive drugs) were 
identified as being of concern in fewer than 50% of all physicians. The awareness of risk factors 
before prescribing is very important in order to minimize adverse effects during treatment. 
Surveys in Italy have shown that 20% of NSAID users were older age and 18% were long-term 
use more than 6 months,27 while about 20% of NSAID users were currently using potentially 
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interacting drugs such as corticosteroids, selective serotonin reuptake inhibitor (SSRI), calcium 
channel blockers or anticoagulants.28 Lack of protection against NSAID risks was often found 
in patients with older age, and those taking anticoagulants in the Swedish prescription.29 This 
finding demonstrates an important problem in Thailand, as many Thai patients have concurrent 
diseases and often receive treatment from multiple physicians (accessing services in different 
departments, clinics, or hospitals). Hence, an overview and review of all drugs being used may 
be difficult in practice, with full information only being available from the patients themselves. 
In this context, physicians should be more concerned about obtaining information on all 
concomitant drugs patients are using. Our study suggests that SK\VLFLDQV¶DZDUHQHVVRIULVN
factors which concern them when prescribing NSAIDs was high, however awareness of risk 
factors might not always lead to appropriate prescribing if information about concurrent 
therapy is not obtained. 
When focusing on information shared with patients, we found that three in four of all 
orthopaedic physicians (75%) claimed they provided ADR information related to prescription 
NSAID to patients, but less frequently provided information about ADR monitoring and 
management (29.7%, and 37.5%, respectively). A previous study in Thai patients taking 
NSAIDs reported that 22.1% of them received side effect information from their physicians, 
but only a small number of patients received monitoring (5.4%) and management information 
(4.2%).26 The present study found that physicians who had face-to-face contact with patients 
more than 50% of all working time, thus had greater opportunities to communicate ADR 
monitoring information, were in fact less likely to provide ADR information about NSAIDs to 
patients. Additionally, physicians who spend more than 5 minutes with patients tended to 
provide information about ADR monitoring to patients less often. It seems that ADR 
monitoring was not viewed as important information to provide to patients, even if physicians 
had more time for advising patients. 
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Moreover, provision of NSAID risk information was also still focused on 
gastrointestinal effects, which approximately 60-90% of all physicians claimed to provide. 
Although 44 physicians (72.1%) reported high blood pressure was often present in patients 
taking NSAIDs, only 10 physicians (15.6%) claimed to inform patients about this as a side 
effect. A previous survey reported approximately 50% of NSAID users received at least one 
item of risk information from their physicians, with gastrointestinal bleeding, heart attack, high 
blood pressure, and renal disease were frequently informed around 30-40% of physicians.15 
Additionally, cardiovascular effects can occur with any NSAIDs, not only for selective COX-
2 NSAIDs, as well as gastrointestinal effects. Hence, all patients should be informed about the 
risk information with NSAIDs by physicians before starting treatment, and patients need to 
perceive this information to weigh the benefits and risks regardless of the class of NSAID 
prescribed.30  
A recent survey in Thai patients and the general public showed that they need to receive 
information related their drugs, and prefer to get information from their physicians and 
pharmacists, but that in practice, only 30% of them received ADR information.31 In this study, 
all orthopaedic physicians had moderate or good attitudes towards providing ADR information 
to patients, however concerns about information causing patiHQWV¶ DQ[LHW\ DQG UHGXFLQJ
adherence to treatment were higher among physicians who claimed not to provide ADR 
information. In contrast, our previous studies showed that majority of NSAID users perceived 
the need to receive ADR information (98%). Moreover, our studies show that receiving ADR 
information was unlikely to increase their anxiety and encourage discontinuity of treatment.26 
Current healthcare is moving towards shared decision making with patients therefore it is very 
important that two-way communication, including discussions about alternative choices of 
treatment, presence of risk factors, is practiced which can impact on health outcomes and 
patient satisfaction.32,33 However, this study showed there is a critical point in physician-patient 
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relationships concerning risk communication, suggesting that the amount of risk 
communication may not always be balanced with information about potential benefits of 
treatments. 
However, a high proportion of physicians, particularly those working at general and 
community hospitals, agreed that describing ADRs to patients can be time-consuming, and that 
a PIL is a suitable information source for patients that they can easily access. In the context of 
Thailand, small hospitals have fewer specialists which may affected the time available to 
provide advice to patients, while pharmacists also have a role in providing information about 
NSAIDs,25,26 these medicines are in widespread use both on prescription and non-prescription 
and safety information needs to be re-enforced. Hence, physician involvement in 
communicating with patients needs to become more embedded into routine practice, to improve 
the safety of these drugs. 
4.1 Limitations of the study 
Our study was conducted in only northeastern region of Thailand, our findings may not be 
generalized to all orthopaedic physicians in Thailand. Moreover, the response rate of this 
survey was low (32.0%), while half of all respondents were working in tertiary hospitals 
because most community hospitals have less number of specialist physicians, and the majority 
of all physicians were male (92.4%). All data were obtained from self-administered 
questionnaire therefore there is a strong possibility that social desirability bias may have 
occurred, and the real provision of risk information in practice was not observed in this study. 
 
5. CONCLUSION 
All orthopaedic physicians had moderate to good level of attitudes towards providing ADR 
information to patients. However, risk information related to NSAIDs was not routinely 
provided by all orthopaedic physician respondents in our survey. Risk monitoring and 
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management information was provided less frequently. Better communication about NSAID 
risks is needed to cover not only gastrointestinal risks, but also cardiovascular and renal risks. 
Orthopaedic physicians are also required to have greater awareness or consideration of 
potential patient risk factors for ADRs from NSAIDs before prescribing NSAIDs. 
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TABLE 1 Respondent demographics 
Characteristics 










Male  34 (89.5) 27 (96.4) 61 (92.4) 0.385b 







Work position     
Instructor physician 18 (47.4) 3 (10.7) 21 (31.8) 0.002a 
Physician  20 (52.6) 25 (89.3) 45 (68.2)  









No. of patients seen per day     
d 30cases 15 (39.5) 3 (10.7) 18 (27.3) 0.010a 
t3cases 23 (60.5) 25 (89.3) 48 (72.7)  
Time spent diagnosis and advising per 1 








Proportion of time spent in direct patient 
contact 
    
d50% of all working time 23 (60.5) 15 (53.6) 38 (57.6) 0.572a 
>  50% of all working time 15 (39.5) 13 (46.4) 28 (42.4)  












TABLE 2 Logistic regression analysis of factors associated with providing information 
Factors 
 





95% CI P-value 
No Yes 
Providing ADR information a  
Proportion of time spent in direct patient contact     
d50% of all working hours 5 (31.2) 31 (64.6) 1   
>  50% of all working hours 11 (68.8) 17 (35.4) 0.249 [0.074,0.837] 0.025 
Providing ADR monitoring informationb 
 
Time spent diagnosis and advice per patient     
d5 minutes  15 (34.9)  12 (63.2) 1   
>5 minutes  28 (65.1)  7 (36.8) 0.297 0.091,0.968 0.044 
Proportion of time spent in direct patient contact     
d 50% of all time 29 (64.4) 7 (36.8) 1   
> 50% of all time 16 (35.6) 12 (63.2) 3.363 1.033,10.947 0.044 
a
 Adjusted for type of hospital, and proportion of time spent in direct patient 
b
 Adjusted for age, work experience, number of patient with diagnosis per day, time spent diagnosis 
















TABLE 3 7KHSK\VLFLDQV¶DZDUHQHVVRISDWLHQWV¶ULVNIDFWRUVEHIRUHSUHVFULELQJ16$,'V 
Risk awareness 












When prescribing non-selective NSAIDs 
      Renal impairment 37 (97.4) 17 (100.0) 11 (100.0) 65 (98.5) 
      History of GI ulcer/bleeding 35 (92.1) 17 (100.0) 11 (100.0) 63 (95.5) 
      History of NSAID allergy 32 (84.2) 13 (76.5) 11 (100.0) 56 (84.8) 
      Use NSAID in long-term 29 (76.3) 14 (82.4) 9 (81.8) 52 (78.8) 
      Patient age > 60 years 27 (71.1) 14 (82.4) 10 (90.9) 51 (77.3) 
When prescribing selective COX-2 NSAIDs 
      Renal impairment 34 (89.5) 14 (82.4) 9 (81.8) 57 (86.4) 
      History of cardiovascular disease 29 (76.3) 12 (70.6) 6 (54.5) 47 (71.2) 
      Patient age > 60 years 25 (65.8) 14 (82.4) 6 (54.5) 45 (68.2) 
      History of GI ulcer/bleeding 22 (57.9) 12 (70.6) 8 (72.7) 42 (63.5) 





















No. of physicians who agreed (%) 
P-value 












1. Patients increase need to know about ADRs. 61 (93.8) 34 (89.5) 27 (100.0) b 14 (87.5) 45 (95.7) b 
2. Informing about ADRs may increase anxiety in patients. 27 (41.5) 14 (36.8) 13 (48.1) a 11 (68.8) 16 (34.0) 0.015a 
3. Physicians should have role in providing ADRs information to 
patients. 
57 (89.1) 34 (91.9) 23 (85.2) b 12 (80.0) 43 (91.5)  b 
4. Information of ADRs may lead to discontinuation of drug by 
patients. 
22 (33.8) 13 (34.2) 9 (33.3) a 10 (62.5) 11 (23.4) a 
5. Explanation of ADR information might be time consuming. 54 (83.1) 28 (73.7) 26 (96.3) b 15 (93.8) 37 (78.7) b 
6. Pharmacists may have a major role in the providing ADR 
information to patients. 
48 (75.0) 25 (67.6) 23 (85.2) a 12 (80.0) 35 (74.5) b 
7. $'5,QIRUPDWLRQFRXOGQRWLPSURYHSDWLHQW¶VFRQILGHQFHIRUVHOI-
reported ADRs. 
37 (56.9) 21 (55.3) 16 (59.3) a 7 (43.8) 30 (63.8) a 
8. There should be a SURFHVVWRLPSURYHSDWLHQW¶VNQRZOHGJHDERXW
ADRs. 
61 (93.8) 35 (92.1) 26 (96.3) b 15 (93.8) 44 (93.6) b 
9. Beside of drug counseling from health professionals, patients should 
receive information leaflet to improve knowledge about medicine. 
56 (86.2) 34 (89.5) 22 (81.5) b 14 (87.5) 40 (85.1) b 
10. 3,/VPD\GHFUHDVHSDWLHQW¶VDGKHUHQFHWRPHGLFDWLRQ 10 (15.4) 8 (21.1) 2 (7.4) b 1 (6.3) 8 (17.0) b 
11. PILs are information source helping patients to monitor ADRs and 
increase confident and accuracy for reporting ADRs 
56 (86.2) 32 (84.2) 24 (88.9) b 13 (81.3) 41 (87.2) b 
12. PILs cannot improve SDWLHQW¶VFDUHIXOQHVV about using medicine 7 (10.8) 4 (10.5) 3 (11.1) b 1 (6.3) 6 (12.8) b 
13. PILs can decrease your workload in part of informing patients about 
ADRs 
51 (78.5) 28 (73.7) 23 (85.2) a 13 (81.3) 37 (78.7) 1.000b 
14. Giving PILs to patient may increase your workload 20 (30.8) 15 (39.5) 5 (18.5) a 7 (43.8) 13 (27.7) a 
15. Pharmaceutical company should provide PILs adequately to all 
patients. 
44 (67.7) 25 (65.8) 19 (70.4) a 12 (75.0) 30 (63.8) a 
16. PILs are reliable information source for providing risk and benefit 
data of drugs to patients 
53 (82.8) 31 (81.6) 22 (84.6) b 12 (75.0) 39 (84.8) b 
17. PILs are source of ADR information that patients can easily access 
to information 
53 (81.5) 27 (71.1) 26 (96.3) b 13 (81.3) 38 (80.9) 1.000b 
Total mean scores 61.15±5.30 60.78±6.35 61.65±3.43 c 59.86±4.70 61.59±5.56 c 
aPearson chi-square ,bFisFKHU¶V([DFWWHVWcIndependent t-test 
